|Bid||42.57 x 2000|
|Ask||43.00 x 2000|
|Day's Range||42.56 - 42.92|
|52 Week Range||36.58 - 44.50|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
Shares of Neothetics Inc. more than doubled Tuesday on heavy volume, after the specialty pharmaceutical company announced an agreement in which a wholly-owned subsidiary of Neothetics will merge with privately ...
President Donald Trump repeated rhetoric from early in his presidency about drug prices being "out of control" and drugmakers "getting away with murder" on Monday, but said nothing ...
Health-care stocks finished dead last in the Standard & Poor's 500 as Republicans tried yet again to repeal and replace the Affordable Care Act. The Cassidy-Graham bill, named for Senator Bill Cassidy, R-La., and Lindsey Graham, R-S.C., was introduced Sept. 13 and appears to be gaining momentum. Cassidy-Graham would get rid of individual and employer mandates and subsidies and rollback Medicaid, among other things.
Eli Lilly and Co.’s (LLY) cardiovascular franchise includes two drugs—Cialis and Effient. These drugs comprise ~15.0% of the company's total revenues.
Jazz Pharmaceuticals expects Defitelio to report revenues in the range of $130 million to $150 million globally in 2017.
On August 3, JAZZ managed to secure regulatory approval from the FDA for its innovative drug, Vyxeos, as a treatment option for two types of acute myeloid leukemia.
Peregrine Pharmaceuticals Inc. said it laid off one-fifth of its workforce, or 60 employees, as part of a cost cutting plan. The biopharmaceutical company expects to save $3.7 million to $4.3 million in ...
Shares of Teva Pharmaceutical Industries Ltd. tumbled 8% in morning trade Monday on heavy volume, putting them on track to close at a 14-year low, as Morgan Stanley turned bearish on the generic drug maker ...
Most large cap U.S. pharmaceuticals companies have already reported second quarter earnings by this point, which means that the focus for the remainder of the year will continue to be macro questions and pressures amid a limited number of catalysts capable of changing sentiment on the sector. Divan writes that positive product news could provide upside for stocks, but this could be offset by fewer important pipeline readouts and the ongoing debate about drug pricing. As we move through the back half of the year, Divan argues that sentiment should improve in the sector if significant reforms focusing on drug pricing appear to remain rather low-priority in Washington.
Shares of Teva Pharmaceuticals Industries Ltd. plunged 10.4% in active premarket trade Thursday, after the drug maker missed fiscal second-quarter profit expectations and slashed its full-year outlook. ...
Bristol-Myers Squibb's (BMY) virology portfolio includes drugs for the treatment of chronic viral diseases and infections such as hepatitis B, hepatitis C, and HIV.
Bristol-Myers Squibb (BMY) is expected to report a rise of ~4.4% in its earnings to $5.1 billion for 2Q17 on July 27, 2017.
Eli Lilly (LLY) surpassed Wall Street analysts’ revenue estimates of $5.21 billion with reported revenues of $5.23 billion during 1Q17.
Allergan's revenues are driven by the strong performance of products under its key brands as well as the inclusion of revenues from LifeCell and other acquisitions.
Pharmaceutical ETFs are securities designed for investors who do not have the capacity to hold many stocks but are interested in diversification of their investments within the pharmaceutical sector. Besides…...
Merck's Gardasil franchise reported total sales of $532 million during 1Q17, representing 41% growth compared to the franchise's 1Q16 sales.